Last checked at 4 Apr 2011 10:28
Oxford BioMedica plc ("Oxford BioMedica" or the "Company")
Annual Information Update for the Twelve Months to 1 April 2011
Oxford BioMedica is providing an annual information update pursuant to Prospectus Rule 5.2 made by the Financial Services Authority.
1. Announcements made via a Regulatory Information Service
Date | Announcement |
21 April 2010 | Board Change - resignation of Nick Woolf |
27 April 2010 | AGM result |
4 May 2010 | Total voting rights update |
5 May 2010 | Holding(s) in Company |
13 May 2010 | Corporate presentation at Rodman & Renshaw conference |
19 May 2010 | Interim management statement |
27 May 2010 | Blocklisting interim review |
14 June 2010 | ProSavin® clinical trial update |
15 June 2010 | Directors' interests in shares - Long Term Incentive Plan award |
17 June 2010 | Holding(s) in Company |
18 June 2010 | Amendment to 5T4 licence with Cancer Research Technology and issue of shares |
24 June 2010 | Collaboration to evaluate TroVax® in mesothelioma |
24 June 2010 | Notice of interim results |
30 June 2010 | Total voting rights update |
1 July 2010 | Notice of R&D presentation for investors and analysts |
1 July 2010 | Award of grant by Motor Neurone Disease Association |
26 July 2010 | FDA approval for TroVax® Phase II study in prostate cancer |
18 August 2010 | Licence agreement with Emergent BioSolutions Inc. |
18 August 2010 | Holding(s) in Company |
24 August 2010 | Interim results |
15 September 2010 | Holding(s) in Company |
22 September 2010 | TroVax® selected by Windhover and Campbell Alliance as one of the "Top 10 Most interesting Oncology Projects to Watch". |
14 October 2010 | TroVax® Phase III data published in journal Clinical Cancer Research |
14 October 2010 | Change of Advisor and Broker |
29 October 2010 | Interim management statement |
9 November 2010 | US IND approval for RetinoStat® |
26 November 2010 | Blocklisting interim review |
13 December 2010 | Proposed Firm Placing and Placing and Open Offer of up to £20 million |
13 December 2010 | Confirmation of underwritten £20 million share issue |
14 December 2010 | Issue of prospectus |
22 December 2010 | ProSavin® clinical trial update |
23 December 2010 | Corporate presentation at JP Morgan Healthcare conference |
7 January 2011 | Result of Open Offer |
7 January 2011 | Result of General Meeting |
10 January 2011 | Directors' interests in shares |
12 January 2011 | Holding(s) in Company |
20 January 2011 | Notice of results |
31 January 2011 | Acquisition of manufacturing facility |
31 January 2011 | Holding(s) in Company |
31 January 2011 | Total voting rights update |
9 February 2011 | Appointment of Head of Manufacturing |
2 March 2011 | Preliminary results for 2010 |
15 March 2011 | TroVax® Phase III data published in journal Cancer Immunology, Immunotherapy |
21 March 2011 | US IND approval for StarGen™ |
21 March 2011 | Board Change - resignation of Dr Alan Kingsman |
22 March 2011 | Director's interest in shares |
31 March 2011 | Annual Report and Accounts and AGM notification |
1 April 2011 | Annual information update |
Details of all regulatory announcements for Oxford BioMedica can be found on the London Stock Exchange website at www.londonstockexchange.com and on the Oxford BioMedica website at http://www.oxfordbiomedica.co.uk
2. Documents filed with Companies House
Date | Document Type | Description |
6 April 2010 | SH01 Return of Allotments of Shares | Allotment 1,873,206 1p Ord. |
27 April 2010 | AGM Special Business | AGM minutes |
28 June 2010 | SH01 Return of Allotments of Shares | Allotment 1,816,523 1p Ord. |
30 September 2010 | AR01 Annual Return | Annual return |
10 January 2011 | SH01 Return of Allotments of Shares | Allotment 400,000,000 1p Ord. |
Copies of documents filed at Companies House can be obtained from Companies House, Crown Way, Cardiff CF14 3UZ or through Companies House Direct at www.direct.companieshouse.gov.uk
3. Documents published or sent to shareholders or filed with the UKLA National Storage Mechanism
Date | Description |
24 August 2010 | Interim Report for 6 months to 30 June 2010 |
13 December 2010 | Prospectus |
7 January 2011 | General Meeting Resolutions |
30 March 2011 | Annual report for the year ended 31 December 2010 and Notice of AGM |
Copies of all the above documents may be obtained from the Company Secretary at the Company's Registered Office:
This annual information update is filed pursuant to Prospectus Rule 5.2 made by the Financial Services Authority and not for any other purpose and by filing this annual information update neither the Company, nor any other person, takes any responsibility for, or makes any representation, express or implied, as to the accuracy or completeness of, the information contained or referred to below herein. The information referred to below is not necessarily up to date as at the date of this annual information update and the Company does not undertake any obligation to update any such information in the future. Furthermore, such information may have been prepared in accordance with the laws or regulations of a particular jurisdiction and may not comply with or meet the relevant standards of disclosure in any other jurisdiction. Neither this annual information update, nor the information referred to below constitutes, by virtue of this communication, an offer of any securities addressed to any person and should not be relied on by any person.
Oxford BioMedica plc
Medawar Centre
Robert Robinson Avenue
The Oxford Science Park
Oxford
OX4 4GA
04 April 2011